List of Excipients in Branded Drug LO LOESTRIN FE

« Back to Dashboard

Last updated: August 9, 2026

Lo Loestrin Fe is a low-dose, four-phase oral contraceptive with a relatively simple tablet platform but meaningful commercial differentiation opportunities in excipient control, dose uniformity, packaging, and adherence support. The product contains norethindrone acetate and ethinyl estradiol in 24 active tablets, followed by two ethinyl estradiol-only tablets and two ferrous fumarate tablets. The strongest opportunities are generic or authorized-generic development, excipient-controlled bioequivalence programs, adherence-oriented packaging, and lifecycle products that preserve the low-estrogen profile while improving tolerability or administration.

Lo Loestrin Fe Excipient Strategy, Patent Position, and Commercial Opportunities

What is the Lo Loestrin Fe formulation?

Lo Loestrin Fe is an oral contraceptive marketed in the United States by Mayne Pharma under a license from Warner Chilcott, a company acquired by Allergan and later integrated into AbbVie. Each 28-day pack contains three tablet types:

Tablet type	Active ingredients	Quantity per tablet	Pack position
Blue active tablet	Norethindrone acetate and ethinyl estradiol	1 mg / 10 mcg	Tablets 1-24
White active tablet	Ethinyl estradiol	10 mcg	Tablets 25-26
Brown tablet	Ferrous fumarate	75 mg	Tablets 27-28

The regimen provides 24 days of combined hormonal contraception, two days of low-dose ethinyl estradiol without norethindrone acetate, and two iron-containing tablets. The product is indicated for pregnancy prevention in females of reproductive potential and is supplied in blister packaging designed to preserve daily sequence and adherence.[1]

The formulation strategy has four commercial characteristics:

1. It uses an unusually low ethinyl estradiol dose of 10 mcg.
2. It separates the combined-hormone phase from the ethinyl estradiol-only phase.
3. It uses ferrous fumarate as a noncontraceptive reminder tablet.
4. It relies on a sequential, calendarized package rather than a single uniform tablet.

These features create formulation and packaging requirements that are more complex than a conventional 21-day combined oral contraceptive.

What excipients are used in Lo Loestrin Fe tablets?

The FDA-approved labeling identifies excipients by tablet category rather than as a single formulation across the entire pack. The inactive ingredients include common oral solid-dose excipients such as lactose monohydrate, microcrystalline cellulose, magnesium stearate, and coloring agents. The ferrous fumarate tablets use a separate excipient system appropriate for an iron-containing placebo tablet.[1]

The principal excipient functions are:

Excipient function	Commercial purpose
Diluent	Provides tablet mass despite the microgram-level ethinyl estradiol dose
Binder	Supports granulation and mechanical strength
Disintegrant	Promotes rapid tablet breakup and dissolution
Lubricant	Supports compression and tablet ejection
Pigment or colorant	Distinguishes the 24 combined tablets, two ethinyl estradiol-only tablets, and two iron tablets
Film coat	Controls appearance, swallowability, identification, and moisture protection
Iron-tablet matrix	Carries ferrous fumarate and creates a visually distinct reminder tablet

At 10 mcg of ethinyl estradiol, dose uniformity is a central manufacturing issue. The drug substance represents a very small fraction of total tablet weight. A generic manufacturer must control blending, segregation, sampling, assay sensitivity, and content uniformity across production batches.

The excipient system must also support rapid and reproducible dissolution. A formulation that changes the lubricant level, granulation process, particle-size distribution, or disintegrant system can alter dissolution even when the nominal active ingredients are identical.

How does the low-dose formulation affect excipient selection?

The 10-mcg ethinyl estradiol dose increases the importance of low-dose blending and analytical control. Excipients are selected less for pharmacologic activity than for their effect on distribution of the active pharmaceutical ingredients throughout the blend.

Dose uniformity

Norethindrone acetate is present at 1 mg, while ethinyl estradiol is present at only 10 mcg in the combined tablets. This 100-fold difference creates a high dilution ratio for ethinyl estradiol. A robust formulation may use:

• Ordered mixing or geometric dilution.
• Controlled active-particle size.
• Low-segregation excipient blends.
• Validated blend sampling.
• Sensitive content-uniformity methods.
• Tight controls on transfer, hopper residence time, and compression speed.

A manufacturer that changes excipient grade without revalidating segregation and assay performance could create regulatory risk even if dissolution remains acceptable.

Compression and friability

The combined tablets must remain small enough for patient convenience while surviving coating, packaging, shipping, and daily handling. Excess lubricant can reduce tablet hardness or slow wetting and dissolution. Excessive compression force can create hard tablets with delayed disintegration.

Moisture and stability

Ethinyl estradiol and norethindrone acetate require stability control within a multi-component blister pack. The iron tablets add a separate chemical and color-stability burden. Packaging selection can therefore be as commercially important as the excipient selection.

Potential controls include:

• Low-moisture film coats.
• High-barrier blister materials.
• Desiccant-supported secondary packaging.
• Tight control of residual moisture.
• Light-protective packaging.
• Colorant compatibility studies.
• Extractables and leachables testing.

The regulatory objective is not simply a long shelf life. It is preservation of assay, content uniformity, dissolution, appearance, and tablet identity through the labeled expiration period.

What formulation patents could protect Lo Loestrin Fe?

The commercial product’s core active combination is relatively straightforward. Patent value is more likely to arise from the specific dosage regimen, low-estrogen composition, tablet sequence, stability profile, packaging system, or manufacturing process than from the use of ordinary excipients such as lactose or magnesium stearate.

Potential claim categories include:

Claim category	Potential commercial value
Low-dose hormonal composition	Protects the specified ratio and amounts of norethindrone acetate and ethinyl estradiol
24/2/2 regimen	Protects the sequence of combined tablets, ethinyl estradiol-only tablets, and iron tablets
Tablet architecture	Covers distinct tablet populations within one 28-day package
Stability formulation	Protects excipient combinations or coatings that preserve low-dose assay and dissolution
Packaging	Covers calendarized blister layouts, barrier materials, or sequence-control features
Manufacturing process	Covers blending, granulation, compression, coating, or segregation-control steps
Method of use	Covers contraception using the low-dose regimen or treatment-related benefits

Ordinary excipient selection is usually weak as a standalone patent strategy. A claim directed broadly to lactose, microcrystalline cellulose, or magnesium stearate would face substantial prior-art risk. Stronger protection would connect the excipient system to a measurable technical result, such as improved content uniformity for 10-mcg ethinyl estradiol, improved stability, controlled dissolution, or reduced impurity formation.

What is the Orange Book status and generic-entry risk for Lo Loestrin Fe?

Lo Loestrin Fe is an FDA-approved small-molecule oral contraceptive, so the principal generic pathway is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A generic applicant generally must demonstrate pharmaceutical equivalence and bioequivalence rather than repeat the full clinical efficacy program.[2]

Relevant regulatory requirements include:

• Matching the active ingredients and strengths.
• Matching the dosage form and route of administration.
• Demonstrating bioequivalence.
• Demonstrating dissolution performance.
• Addressing the multiple tablet types in the 28-day package.
• Providing labeling that is consistent with the reference listed drug.
• Certifying against relevant Orange Book patents.

The Orange Book analysis should distinguish between:

1. Listed patents that may be subject to a Paragraph IV certification.
2. Unexpired method-of-use patents that may not block approval for all uses.
3. Pediatric exclusivity, if applicable.
4. Regulatory exclusivity, if any.
5. Patents that have expired but remain relevant to historical litigation.

A current Orange Book search is required to identify the live patent list, expiration dates, and any pediatric extensions. Patent status can change through expiration, terminal disclaimers, delisting, court decisions, or settlement agreements.[3]

Generic entry risk is structurally significant because Lo Loestrin Fe is a small-molecule product with no biosimilar barrier. The principal barriers are formulation replication, analytical sensitivity, packaging complexity, patent certifications, and commercial scale rather than clinical-development cost.

When could generic manufacturers enter the Lo Loestrin Fe market?

Generic entry depends on the earliest of several events:

• Expiration of relevant patents.
• Successful Paragraph IV litigation.
• A settlement permitting an earlier launch.
• A license or authorized-generic arrangement.
• Regulatory approval with a noninfringing labeling position.
• Commercial launch after the reference product’s exclusivity period.

A generic applicant may pursue a full formulation match or a composition that differs in inactive ingredients while remaining pharmaceutically equivalent. Inactive ingredients can differ unless the difference creates a safety concern, changes performance, or affects labeling requirements.

The 28-day pack creates a practical hurdle. A generic product must reproduce the correct tablet sequence and avoid medication errors. A three-tablet-color system also creates trademark and trade-dress considerations, although color alone does not create unrestricted exclusivity.

Generic launch scenarios

Scenario	Likely market effect
First generic launch	Price reduction with initial share capture and payer substitution
Multiple generic launches	Rapid erosion in pharmacy benefit and managed-care channels
Authorized generic	Lower-priced competition controlled or licensed by the brand owner
Delayed generic entry	Continued premium pricing and stronger brand retention
Formulation-based 505(b)(2) product	Potential differentiation through tolerability, packaging, or administration

The most commercially attractive generic opportunity is a reliable, low-cost product with high content-uniformity performance and a blister pack that minimizes dispensing errors.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target the product category through performance rather than direct ingredient substitution. The strongest opportunities relate to low-dose oral hormonal products.

Low-segregation excipient systems

A co-processed filler-binder or engineered excipient blend can help manufacturers maintain uniform distribution of microgram-level actives. Commercial value increases if the supplier can document:

• Narrow particle-size distribution.
• Low segregation during transfer.
• Consistent bulk density.
• Low moisture variability.
• Compatibility with direct compression.
• Reduced blend time.
• Improved content-uniformity capability.

Direct-compression platforms

Direct compression can reduce solvent use, shorten processing time, and simplify scale-up. The excipient must provide adequate flow, compactibility, and disintegration without compromising dissolution.

Taste and swallowability support

Although Lo Loestrin Fe tablets are swallowed whole, smaller tablets, smoother coatings, and lower friability can improve patient experience. These improvements are more likely to support a product-development or line-extension strategy than to justify a standalone patent.

Moisture-barrier and film-coating systems

A coating that reduces moisture ingress while preserving rapid disintegration may support a differentiated generic or 505(b)(2) product. The strongest opportunity would involve a demonstrated stability advantage under accelerated and long-term conditions.

Iron-tablet optimization

The ferrous fumarate tablets are commercially relevant because they complete the daily pack and maintain the contraceptive routine. Opportunities include:

• Improved color stability.
• Lower tablet staining.
• Reduced odor or metallic taste.
• Improved mechanical strength.
• Better compatibility with the blister.
• Distinct visual identification without confusing the active tablets.

Any change must preserve the role of the tablets as clearly identified nonhormonal tablets and avoid medication errors.

How strong is the patent estate for excipient-based Lo Loestrin Fe products?

The patent strength of an excipient-based product depends on claim specificity and technical evidence.

Patent approach	Relative strength
Broad use of common excipients	Low
Specific excipient ratios without a demonstrated effect	Low to moderate
Low-dose content-uniformity composition with supporting data	Moderate
Stability-enhancing formulation with comparative data	Moderate to strong
Packaging and tablet-sequence system with functional limitations	Moderate
Manufacturing process that reduces segregation or impurities	Moderate
Regimen patent covering the complete dosing sequence	Potentially strong, subject to prior art and validity

Patent applicants should generate comparative data against a conventional formulation. Useful endpoints include assay variability, blend uniformity, dissolution at multiple pH levels, impurity growth, tablet hardness, friability, moisture uptake, and stability after blister-packaging.

Trade-secret protection may be more practical for blending order, process parameters, sampling plans, and scale-up controls. These details can be difficult to reverse engineer from the finished product and may be less vulnerable to patent invalidity challenges.

Which companies could compete with Lo Loestrin Fe?

Competition comes from several segments:

1. Generic manufacturers developing norethindrone acetate and ethinyl estradiol products.
2. Branded combined oral contraceptive companies offering different estrogen doses.
3. Manufacturers of progestin-only pills.
4. Long-acting reversible contraceptive providers.
5. Digital and subscription contraceptive services that compete through access and adherence programs.
6. Authorized-generic or licensed-product channels.

The closest product competition is from oral contraceptives using norethindrone acetate and ethinyl estradiol, although dose, regimen, tablet count, and estrogen exposure can differ. Lower-cost alternatives may not be clinically interchangeable from a patient or prescriber perspective if they use a different hormone dose or schedule.

Lo Loestrin Fe’s commercial positioning depends on the low estrogen dose, the 24-day combined-hormone schedule, and the branded pack design. Those attributes can support continued demand but do not eliminate substitution risk after generic entry.

What licensing and lifecycle strategies are available?

The principal licensing options include:

• Authorized-generic licensing to a selected generic manufacturer.
• Regional licensing where regulatory approvals and patent terms differ.
• Co-development of a stability-enhanced formulation.
• Licensing of a high-barrier blister or calendar-packaging system.
• Supply agreements for engineered excipient platforms.
• 505(b)(2) development using the reference product as the clinical and safety bridge.

A brand owner can also use lifecycle management without changing the active ingredients. Options include a new package configuration, improved labeling, adherence technology, or a reformulated tablet with documented stability or handling benefits. These approaches must provide a real regulatory or commercial advantage because simple excipient substitution is unlikely to sustain a premium after generic competition.

What geographic coverage matters for Lo Loestrin Fe?

The United States is the key jurisdiction for Orange Book and Paragraph IV analysis. Other markets use different patent, regulatory, and substitution frameworks.

Relevant geographic issues include:

• National patent expiration dates.
• Regional differences in pediatric or regulatory exclusivity.
• Variations in generic substitution rules.
• Local requirements for iron-containing reminder tablets.
• Country-specific colorant and excipient restrictions.
• Packaging and serialization requirements.
• Different prescription and reimbursement systems.

An excipient supplier with global ambitions should maintain region-specific compliance files for elemental impurities, residual solvents, nitrosamines, allergens, colorants, and pharmacopoeial status. The same excipient grade may not have identical regulatory acceptance in every market.

What revenue exposure exists if Lo Loestrin Fe loses exclusivity?

Revenue exposure is driven by prescription volume, net price, payer mix, generic substitution, and the number of competing entrants. A first generic can reduce net pricing before broad generic penetration occurs. Multiple entrants typically create stronger price erosion.

The commercial impact is likely to be concentrated in:

• Retail pharmacy substitution.
• Medicaid and managed-care formularies.
• Employer-sponsored insurance.
• Cash-pay contraceptive channels.
• Mail-order dispensing.

Brand retention can remain stronger where patients value the exact tablet sequence, tolerate the product well, or receive it through channels that restrict substitution. The principal business decision is whether to maximize late-life brand revenue, launch an authorized generic, license a challenger, or redirect investment toward a differentiated successor product.

Key Takeaways

• Lo Loestrin Fe uses 24 combined norethindrone acetate/ethinyl estradiol tablets, two ethinyl estradiol-only tablets, and two ferrous fumarate tablets.
• The 10-mcg ethinyl estradiol dose makes blend uniformity, assay sensitivity, segregation control, and dissolution critical.
• Common excipients have limited standalone patent value unless linked to a measurable technical effect.
• The strongest excipient opportunities involve low-dose uniformity, moisture protection, stability, direct compression, and blister-pack compatibility.
• Generic competition is structurally credible because the product is a small-molecule oral contraceptive eligible for an ANDA pathway.
• Patent and exclusivity analysis must use the current FDA Orange Book and applicable court or settlement records.
• Authorized generics, excipient-enabled reformulations, improved packaging, and 505(b)(2) products are the main commercial lifecycle options.
• Iron-tablet design matters for adherence, pack identity, and medication-error prevention even though the tablets are not contraceptively active.

FAQs

Can a generic Lo Loestrin Fe use different excipients?

Yes. A generic may use different inactive ingredients if it remains pharmaceutically equivalent, bioequivalent, stable, and acceptable under FDA requirements. The applicant must address any differences that affect safety, performance, labeling, or patient administration.

Is ferrous fumarate necessary for Lo Loestrin Fe contraceptive activity?

No. Ferrous fumarate is contained in the two reminder tablets and does not provide the contraceptive effect. Its commercial role is connected to the 28-day pack and daily administration routine.

Can an excipient supplier patent a Lo Loestrin Fe generic formulation?

Yes, but the strongest claims would generally require a specific composition or process tied to a demonstrated result, such as improved content uniformity, stability, dissolution, or reduced segregation. Broad claims covering routine excipients are more vulnerable to prior art.

Does Lo Loestrin Fe have biosimilar risk?

No. Lo Loestrin Fe is a chemically synthesized small-molecule drug. Its competitive risk comes from generic drugs filed through the ANDA pathway, not biosimilars filed under the biologics framework.

What is the most defensible commercial opportunity around Lo Loestrin Fe?

The most defensible opportunity is a performance-based formulation or packaging platform that improves low-dose content uniformity, stability, manufacturing yield, or adherence while preserving the approved dosage regimen and bioequivalence profile.

References

1. U.S. Food and Drug Administration. (2023). Lo Loestrin Fe prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book